This site is intended for healthcare professionals only


The role of anxiety sensitivity-physical concerns in terms of quit day withdrawal symptoms and cravings: A pilot test among smokers with asthma

Andrienne L Johnson, Emily M O’Bryan, Kristen M Kraemer, et al.
J Asthma 2018;26:1–6
doi: 10.1080/02770903.2018.1437175.

Compared with their non-asthmatic counterparts, asthmatic patients often experience increased risk of relapse during the first months of their quit attempt due to prolonged withdrawal symptoms and cravings. Such experiences are believed to be linked to anxiety sensitivity (AS), a cognitive-affective vulnerability factor defined as the fear of arousal-related sensations due to perceived negative consequences. In this study, Dr Adrienne L Johnson and colleagues aimed to explore the predictive ability of precessation AS-physical concerns on the likelihood of withdrawal symptoms and cravings during a patient’s quit attempt. Controlling for the effects of cognitive and social domains of AS, this study specifically explored the effect of AS physical-concerns on the experience of these symptoms. Results showed that increased AS physical-concerns at precessation significantly predicted greater quit-day withdrawal symptoms and urge to smoke. The researchers concluded that asthmatic smokers are more likely to experience quit-day withdrawal symptoms if they experience AS-physical concerns. Based on this, AS concerns should be targeted as a smoking cessation strategy to help avoid increased withdrawal symptoms and cravings in asthmatic patients. Nicotine replacement therapies should also be optimised to help combat the experience of these symptoms.

Other summaries

Media partners

Developed in partnership with

Funded by

Media partners:

The Primary Care Respiratory Academy has been developed and is produced by Cogora, the publisher of Pulse, Nursing in Practice, Healthcare Leader, Management in Practice and The Pharmacist working in partnership with PCRS.

All educational content for the website and videos has been initiated and produced by PCRS and Cogora.

The Primary Care Respiratory Academy is sponsored by Chiesi Ltd.